Literature DB >> 24643043

The Cosmc connection to the Tn antigen in cancer.

Tongzhong Ju1, Rajindra P Aryal1, Matthew R Kudelka1, Yingchun Wang1, Richard D Cummings1.   

Abstract

The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser/Thr (Tn antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Galβ1-3GalNAcα1-O-Ser/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 β3-galactosyltransferase or C1GalT). Formation of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by Cosmc on the X-chromosome (Xq24 in humans, Xc3 in mice). Cosmc resides in the endoplasmic reticulum (ER) and prevents misfolding, aggregation, and proteasome-dependent degradation of newly synthesized T-synthase. Loss of expression of active T-synthase or Cosmc can lead to expression of the Tn antigen, along with its sialylated version Sialyl Tn antigen as observed in several cancers. Both genetic and epigenetic pathways, in addition to potential metabolic regulation, can result in abnormal expression of the Tn antigen. Engineered expression of the Tn antigen by disruption of either C1GalT (T-syn) or Cosmc in mice is associated with a tremendous range of pathologies and engineered expression of the Tn antigen in mouse embryos leads to embryonic death. Studies indicate that many membrane glycoproteins expressing the Tn antigen and/or truncated O-glycans may be dysfunctional, due to degradation and/or misfolding. Thus, expression of normal O-glycans is associated with health and homeostasis whereas truncation of O-glycans, e.g. the Tn and/or Sialyl Tn antigens is associated with cancer and other pathologies.

Entities:  

Keywords:  Cosmc; T-synthase; Tn antigen; cancer

Mesh:

Substances:

Year:  2014        PMID: 24643043      PMCID: PMC5808877          DOI: 10.3233/CBM-130375

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  204 in total

1.  Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (Anti-Tn).

Authors:  J DAUSSET; J MOULLEC; J BERNARD
Journal:  Blood       Date:  1959-10       Impact factor: 22.113

2.  The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T-synthase.

Authors:  Rajindra P Aryal; Tongzhong Ju; Richard D Cummings
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

3.  A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin.

Authors:  A Leppänen; P Mehta; Y B Ouyang; T Ju; J Helin; K L Moore; I van Die; W M Canfield; R P McEver; R D Cummings
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

4.  Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection.

Authors:  Maria Van der Sluis; Barbara A E De Koning; Adrianus C J M De Bruijn; Anna Velcich; Jules P P Meijerink; Johannes B Van Goudoever; Hans A Büller; Jan Dekker; Isabelle Van Seuningen; Ingrid B Renes; Alexandra W C Einerhand
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

5.  Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.

Authors:  T Kohsaki; I Nishimori; H Nakayama; E Miyazaki; H Enzan; M Nomoto; M A Hollingsworth; S Onishi
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

6.  Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase.

Authors:  J E Hansen; O Lund; J Engelbrecht; H Bohr; J O Nielsen; J E Hansen
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

7.  Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma.

Authors:  U Schumacher; D Higgs; M Loizidou; R Pickering; A Leathem; I Taylor
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

Review 8.  Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.

Authors:  S Hakomori
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

9.  Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo.

Authors:  Hiroshi Ando; Takefumi Matsushita; Masako Wakitani; Takashi Sato; Sachiko Kodama-Nishida; Kenji Shibata; Kenya Shitara; So Ohta
Journal:  Biol Pharm Bull       Date:  2008-09       Impact factor: 2.233

10.  Persistent Tn polyagglutination syndrome during febrile neutropenia: a case report and review of the literature.

Authors:  Arturo Loaiza-Bonilla; Daniel Horowitz; Sheenu Sheela; Anupa Baral; Gabriel Tinoco; Christos Kyriakopoulos
Journal:  J Med Case Rep       Date:  2011-01-14
View more
  56 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

Review 2.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 3.  Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD.

Authors:  Matthew R Kudelka; Sean R Stowell; Richard D Cummings; Andrew S Neish
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-24       Impact factor: 46.802

4.  "Stuck on sugars - how carbohydrates regulate cell adhesion, recognition, and signaling".

Authors:  Richard D Cummings
Journal:  Glycoconj J       Date:  2019-07-02       Impact factor: 2.916

Review 5.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

Review 6.  C-type lectin receptors in the control of T helper cell differentiation.

Authors:  Teunis B H Geijtenbeek; Sonja I Gringhuis
Journal:  Nat Rev Immunol       Date:  2016-06-13       Impact factor: 53.106

7.  Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin.

Authors:  Sophie A Dusoswa; Jan Verhoeff; Erik Abels; Santiago P Méndez-Huergo; Diego O Croci; Lisan H Kuijper; Elena de Miguel; Valerie M C J Wouters; Myron G Best; Ernesto Rodriguez; Lenneke A M Cornelissen; Sandra J van Vliet; Pieter Wesseling; Xandra O Breakefield; David P Noske; Thomas Würdinger; Marike L D Broekman; Gabriel A Rabinovich; Yvette van Kooyk; Juan J Garcia-Vallejo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

Review 8.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

9.  Cytotoxic protein from the mushroom Coprinus comatus possesses a unique mode for glycan binding and specificity.

Authors:  Peilan Zhang; Kunhua Li; Guang Yang; Changqing Xia; Jane E Polston; Gengnan Li; Shiwu Li; Zhao Lin; Li-Jun Yang; Steven D Bruner; Yousong Ding
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

10.  Isotopic labeling with cellular O-glycome reporter/amplification (ICORA) for comparative O-glycomics of cultured cells.

Authors:  Matthew R Kudelka; Alison V Nairn; Mohammed Y Sardar; Xiaodong Sun; Elliot L Chaikof; Tongzhong Ju; Kelley W Moremen; Richard D Cummings
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.